Confidential information

2 trials

Sponsors

Tahara Eriko, Imazu Susumu

Conditions

Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3.epNEC (except for MCC,MTC,Grade 3 neuroendocrine tumour) LCNEC NEC of unknown primary site

Phase 1

A study to test different doses of BI 764532 combined with ezabenlimab in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3.

Active, not recruitingJPRN-jRCT2031220716

Tahara ErikoSmall Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3.

Start: 2023-06-27Target: 4Updated: 2026-06-29

DAREON-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers

RecruitingJPRN-jRCT2031230511

Imazu SusumuepNEC (except for MCC,MTC,Grade 3 neuroendocrine tumour) LCNEC NEC of unknown primary site

Start: 2023-12-20Target: 55Updated: 2026-06-29